マサチューセッツ州における膵臓がんの臨床試験
マサチューセッツ州内の拠点で、膵臓がんに関する47件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/10/02更新 · NCT07059884A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT05372614A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07090499A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07127874Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Dana Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07621718Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute (DFCI), Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07252232Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06445062A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Investigative Site US022, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07522073Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
- Dana-Farber Cancer Institute, Boston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/21更新 · NCT06271291A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Massachusetts General Hospital - Main Campus, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07349537A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0124, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07492680Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
- Boston Children's Hospital, Boston
被験者募集中観察研究
17歳以下 · 全性別 · 2026/09/11更新 · NCT06651580Resilience and Equity in Aging, Cancer, and Health (REACH)
- Dana-Farber Cancer Institute, Boston
被験者募集中
65歳以上 · 全性別 · 2026/09/10更新 · NCT04674267A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07644559Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Dana-Farber Cancer Institute, Brookline
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT05245500Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
被験者募集中第1/2相
18歳〜130歳 · 全性別 · 2026/08/12更新 · NCT05417594Pancreatic Cancer Early Detection Consortium
- Massachusetts General Hospital, Boston
- Umass Memorial Medical Center, Worcester
被験者募集中観察研究健康なボランティア歓迎
18歳〜90歳 · 全性別 · 2026/07/22更新 · NCT04970056A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
- Dana-Farber/Massachusetts General Hospital, Inc, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT07300150A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/29更新 · NCT07458347Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Boston
- Research Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/10更新 · NCT06835569Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/08更新 · NCT04890613Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/03更新 · NCT06040541Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中早期第1相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/05/29更新 · NCT06122896Video Education With Result Dependent dIsclosure
- Dana Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/05/22更新 · NCT05225428Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/15更新 · NCT05379985Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT06239194A Study of MGC028 in Participants With Advanced Solid Tumors
- Mass General Brigham, Boston
- Dana Farber/Harvard Cancer Center, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/27更新 · NCT06723236A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/22更新 · NCT07020221Prehab for Pancreatic Cancer Surgery
- UMass Memorial Medical Center, Worester
被験者募集中
18歳以上 · 全性別 · 2026/04/03更新 · NCT07478185Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
- Beth Israel Deaconess Medical Center - Division of Hematology/Oncology, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/03更新 · NCT06850623A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/18更新 · NCT06244771Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
- Massachusetts General Hospital, Boston
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/02/27更新 · NCT04485286Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
- Dana Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/02/19更新 · NCT05356117A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- Ohio State University-Telemedicine, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/17更新 · NCT06906562The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/02/02更新 · NCT06861088ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。